US 9,308,192 B2Granted

Use of NRF2 inducers to treat epidermolysis bullosa simplex and related diseases

AssigneeThe Johns Hopkins University

InventorsPierre A. Coulombe, Michelle L. Kerns

Life of this patent

Estimating the term…

Abstract

The present invention relates to methods and compositions for the prevention and treatment of keratin-based skin diseases. In particular, the application describes compositions and methods of treating a patient suffering from skin blistering comprising the use of phase II enzyme inducers.

Claims47

Dependent claims

A method for treating or preventing skin blistering in a patient in need thereof or at risk of developing skin blistering, comprising administering to the patient a composition comprising a therapeutically effective amount of an Nrf2 inducer.

Dependencies are inferred from the claim text.

Facts

Application: 14/025,485Filed 12 Sep 2013 · continuation
Priority: 20 Jul 2007
Published: US 2014/0243267 A128 Aug 2014
Granted: 12 Apr 2016
Term ends: Not estimatedThe source records don’t support an estimate.

Classification9 codes

A61K 38/1825
Growth factors; Growth regulators: fibroblast growth factor [FGF]
A61K 9/0014
Galenical forms characterised by the site of application: skin, i.e. galenical aspects of topical compositions
A61K 31/00
Medicinal preparations containing organic active ingredients
A61K 31/26
Esters, e.g. nitroglycerine, selenocyanates: cyanate or isocyanate esters; Thiocyanate or isothiocyanate esters

Family

Application60/929,985Us provisional application · filed 20 Jul 2007
PCT/US2008/008694Parent of this continuation · filed 17 Jul 2008
US 2014/0243267 A1Pre-grant publication · published 28 Aug 2014
Application12/690,494Parent of this continuation
US 2011/0003747 A1Published application
US 9,308,192 B2This patent

From the US filing history. Foreign family members aren’t listed.

Timeline

Citations

Open elsewhere

patentgrep

Loading patent…

patentgrepSearch patents

Back to results